Semaglutide (Ozempic, Wegovy, Rybelsus): One Receptor, Three Outcome Trials

The short version

Semaglutide (Ozempic, Wegovy, Rybelsus) is a laboratory-made copy of GLP-1, a hormone the gut releases after eating. Those three brand names all contain the same peptide; they differ in what the product was approved to treat and in whether it is an injection or a tablet. Natural GLP-1 tells the pancreas to release insulin, tells the stomach to empty more slowly, and tells the brain that the meal is finished — then it breaks down within about two minutes.

Semaglutide does the same job but lasts roughly a week. Two small changes to the molecule block the enzyme that would destroy it, and a fatty-acid arm makes it stick to a blood protein that keeps it out of the kidneys. That is the entire trick behind a once-weekly injection.

Most of its effect on body weight happens in the brain rather than the gut. It reaches appetite circuits in the hypothalamus and brainstem, switches on the neurons that signal fullness, and quietens the ones that drive hunger. People eat less because they want less, not because their metabolism speeds up.

It is an approved prescription medicine, and this page is a summary of published research — not advice, and not a dose.

What it is

Semaglutide is a 31-amino-acid acylated analogue of human glucagon-like peptide-1, sharing roughly 94% sequence homology with the native hormone. It is a glucagon-like peptide-1 receptor agonist — an incretin mimetic, in the pharmacological shorthand.

Three structural modifications carry the whole pharmacokinetic profile:

• Position 8 alanine replaced by alpha-aminoisobutyric acid (Aib). This blocks cleavage by dipeptidyl peptidase-4 (DPP-4), the enzyme that clears native GLP-1 within minutes.
• Position 34 lysine replaced by arginine. This leaves a single free lysine at position 26 as the sole acylation site.
• A C18 fatty di-acid side chain at lysine-26, attached through a glutamic-acid/ADO spacer. The lipid arm binds strongly but reversibly to serum albumin, which protects the peptide from renal clearance and metabolism. This is the structural basis for once-weekly administration.

It is approved in multiple indications and two formulations — a once-weekly subcutaneous injection, marketed as Ozempic and as Wegovy, and a once-daily oral tablet, marketed as Rybelsus. The approved indications span type 2 diabetes mellitus, chronic weight management, reduction of major adverse cardiovascular events in adults with established cardiovascular disease and overweight or obesity, and metabolic dysfunction-associated steatohepatitis. The separate brand names track separate approved indications rather than separate molecules; the peptide is the same in each.

The trial literature below reports everything under the drug name, and so does this page. Where a study is described, it is described as the investigators reported it.

How it works

Semaglutide activates the GLP-1 receptor, and the consequences divide cleanly into a pancreatic set and a central set.

In the pancreas, it potentiates glucose-dependent insulin secretion from beta cells and suppresses inappropriate glucagon release from alpha cells. The word glucose-dependent matters clinically: the insulin response scales with circulating glucose, which is why the compound does not, on its own, drive blood sugar below normal in the way an insulin secretagogue can.

In the gut, it slows gastric emptying. This blunts the post-meal glucose spike and prolongs the sensation of fullness. It is also the mechanistic origin of most of the drug's tolerability problems — the nausea is not incidental to how it works, it is downstream of it.

In the brain, and this is where the weight effect actually lives, it reaches the hypothalamic arcuate nucleus and the brainstem area postrema and parabrachial nucleus. There it activates anorexigenic POMC/CART neurons and inhibits orexigenic NPY/AgRP neurons, reducing food intake and shifting food preference. Notably, it does this without raising energy expenditure. The weight change is an intake effect, not a metabolic-rate effect — a distinction that separates it sharply from the glucagon-containing agents further down this desk.

GLP-1 receptors are also expressed in cardiovascular and renal tissue, which is the standing hypothesis for the pleiotropic outcome benefits described below.

Mechanistic targets: pancreatic beta-cell and alpha-cell GLP-1 receptors; hypothalamic arcuate nucleus; brainstem area postrema and parabrachial nucleus; gastric smooth muscle and vagal afferents; cardiovascular and renal GLP-1 receptors.

What the trials show

Semaglutide's evidence base is unusual in this class in that it extends beyond weight and glycaemia into hard clinical outcomes.

Weight. In the STEP 1 randomised trial of 1,961 adults with overweight or obesity and without diabetes, once-weekly subcutaneous semaglutide at the 2.4 mg study dose produced a mean body-weight change of -14.9% from baseline at week 68, against -2.4% on placebo — a treatment difference of roughly 12.4 percentage points ^[4].

Cardiovascular outcomes. SELECT randomised 17,604 adults with established cardiovascular disease and a body-mass index of 27 or above, but without diabetes. The once-weekly 2.4 mg study arm reduced the primary composite of cardiovascular death, non-fatal myocardial infarction and non-fatal stroke, with a hazard ratio of 0.80 (95% CI 0.72–0.90; P<0.001) — a 20% relative risk reduction ^[3].

Kidney outcomes. FLOW randomised 3,533 people with type 2 diabetes and chronic kidney disease. The once-weekly 1.0 mg study arm reduced major kidney-disease events — kidney failure, a 50% or greater decline in eGFR, or kidney or cardiovascular death — with a hazard ratio of 0.76 (95% CI 0.66–0.88), a 24% lower risk than placebo ^[2].

Head to head. SURMOUNT-5 randomised 751 adults with obesity to maximum tolerated doses of tirzepatide or semaglutide for 72 weeks. Mean weight change was -13.7% for semaglutide against -20.2% for tirzepatide, a statistically significant advantage for the dual agonist (P<0.001) ^[1]. Semaglutide is the benchmark, and in that trial it was beaten.

Safety synthesis. A dedicated safety review concluded an overall favourable risk-benefit profile in type 2 diabetes, with mostly mild-to-moderate transient gastrointestinal effects — nausea in roughly one-third of patients — an increased risk of biliary disease, and pancreatic and thyroid-cancer signals for which definitive conclusions cannot yet be drawn given the low event counts ^[5].

What to watch: reported effects and cited cautions

This section carries two very different classes of information, and the labels are not decoration.

Community reports — anecdotal, not clinical evidence

The following comes from patient-review aggregators and research-use communities. It is anecdotal, not clinical evidence: uncontrolled, self-selected, unverified, and impossible to audit. No doses accompany any of it, and none of it establishes cause.

Reported as beneficial. The most frequently described effect by a wide margin is appetite suppression — what people call "food noise" going quiet, often within the first week or two. Reviewers describe feeling full sooner, eating a third to a half of former portions, and stopping the constant mental negotiation about the next meal. Closely behind it: sharply reduced cravings for sugar and sweets, and fried or greasy food losing its appeal, sometimes becoming actively off-putting. Weight loss is reported by the overwhelming majority, usually described as steady over months with the pace slowing after the early period, and usually attributed to eating far less rather than to any change in activity. Among people with type 2 diabetes, markedly improved blood-sugar and A1C readings are a common theme. A recurring secondary observation is that the urge to drink alcohol fades alongside food cravings.

Reported as adverse. Nausea is the single most reported problem, mentioned by roughly a third of reviewers, sometimes escalating to vomiting; it tends to peak in the first weeks and after each dose increase and often eases within a week or two. A distinctive complaint is foul, sulfurous "egg" burps, frequently accompanied by bloating and a sense of food sitting too long. Bowel habits are commonly disrupted in both directions, sometimes alternating. Acid reflux and heartburn appear alongside the burping and bloating. Fatigue in the first day or two after each injection and through the early weeks is commonly described. Some report active food aversions, a metallic taste and an unpleasant heightened sensitivity to smells, and a few report appetite suppression going so far that eating becomes something they have to remember to do. Hair shedding and a hollowed or gaunt face are reported by a smaller group, usually a few months in, and are widely attributed by those reporting them to the speed of weight loss rather than the drug. Headaches, lightheadedness and minor injection-site reactions round out the list.

Cited cautions from the clinical literature

• Gastrointestinal intolerance, especially during dose escalation. Nausea, vomiting, diarrhoea and constipation are the dominant adverse effects in trials and the leading cause of discontinuation; nausea was reported in roughly one-third of patients in a dedicated safety review ^[5]. This is mechanistic rather than incidental — the slowed gastric emptying that produces the effects is part of how the drug works.
• Medullary thyroid carcinoma and MEN-2 (boxed warning). The class carries a boxed warning derived from rodent studies in which C-cell tumours occurred at supratherapeutic exposures. Human data do not establish a clear increase in thyroid cancer, and the signal should be read as unconfirmed in humans ^[5]; a personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia type 2 is nonetheless treated as a contraindication on the strength of the animal finding.
• Acute pancreatitis (class warning). A recognised class warning; treatment is conventionally stopped if pancreatitis is suspected. The dedicated safety review frames pancreatic signals as ones on which definitive conclusions cannot yet be drawn owing to low incidence, rather than as confirmed associations ^[5].
• Gallbladder and biliary disease. An increased risk of biliary disease including cholelithiasis is a real trial and pharmacovigilance finding, attributed largely to the rate and magnitude of weight loss rather than direct drug toxicity ^[5].
• Pre-existing diabetic retinopathy with rapid glycaemic correction. Monitoring is advised where glycaemia is corrected rapidly in people who already have retinopathy; the leading interpretation is early worsening driven by the speed of correction rather than retinal toxicity ^[5].
• Loss of lean mass. Body-composition substudies in the weight-management programme found the weight lost comprised both fat and a meaningful proportion of lean tissue, raising a sarcopenia concern particularly in older adults and motivating research into protein intake and resistance training.
• Weight regain after discontinuation. Stopping is followed by substantial regain, with cardiometabolic improvements reverting toward baseline. This frames obesity pharmacotherapy as chronic rather than curative.
• Pregnancy. Contraindicated per approved labelling. Because the elimination half-life is approximately one week, with effectively complete clearance only around five weeks after the last dose, label guidance advises discontinuation well in advance of a planned pregnancy.
• The oral formulation requires strict fasted administration. Oral semaglutide, marketed as Rybelsus, is co-formulated with the absorption enhancer SNAC and has very low oral bioavailability, so administration errors can substantially reduce the absorbed dose. This is a formulation requirement, not a toxicity.
• Narrow-therapeutic-index oral drugs during titration. A systematic review found delayed gastric emptying generally does not produce clinically significant interactions, but advised monitoring for narrow-therapeutic-index oral medicines during dose escalation.

What remains unknown

The unresolved list is shorter than for the newer agents on this desk, but it is not empty.

The thyroid and pancreatic cancer signals are unresolved rather than refuted: event counts are too low for definitive conclusions ^[5]. Neuropsychiatric reports including depression and suicidality have appeared in pharmacovigilance databases and remain under surveillance; controlled trials have not established a causal link. The clinical significance of lean-mass loss — whether it translates into measurable functional decline, and in whom — is still being characterised, and few studies have measured objective physical function directly.

The compounded-supply question is regulatory rather than pharmacological but is squarely relevant to readers. During the federally declared shortage, compounding pharmacies produced semaglutide; regulators documented dosing errors, adverse events requiring hospitalisation, and products containing unverified or non-pharmaceutical active ingredients. After the shortage was declared resolved in 2025 those pathways were curtailed, leaving ongoing regulatory and telehealth uncertainty. Nothing in the approved-product evidence base transfers to material of unverified identity and purity.

Where it fits in metabolic research

Semaglutide is the axis this entire category rotates around. It was the agent that demonstrated a peptide could produce weight loss at a magnitude previously reserved for surgery, and then went further and showed that the effect carried into hard cardiovascular ^[3] and renal ^[2] endpoints.

That makes it the comparator of record. Tirzepatide is interesting precisely because it beat semaglutide head to head ^[1]. Retatrutide is interesting because its phase 2 weight figures exceed both, though against placebo rather than against either approved drug ^[15]. Tesamorelin sits outside the comparison entirely, working on a different axis for a different endpoint.

The open frontier for semaglutide is no longer how much weight but which organ systems. The kidney result ^[2] and the metabolic liver disease approval both point the same direction: an agent that started as a glucose drug, became a weight drug, and is now being evaluated as a cardiometabolic and organ-protective one. The comparison page places all four side by side.